Want to see JP:4586 full AI Analyst Report?

Medrx Co., Ltd. (4586) Price & Analysis

0 Followers

4586 Stock Chart & Stats

¥113.00

¥2.00(2.50%)

At close: Jan 08 4:00 PM EST

¥113.00

¥2.00(2.50%)

Day’s Range― - ―

52-Week Range¥48.00 - ¥225.00

Previous CloseN/A

Volume596.00K

Average Volume (3M)2.57M

Market Cap

¥3.07B

Enterprise Value¥1.62B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-28.53

Shares Outstanding60,271,100

10 Day Avg. Volume1,116,360

30 Day Avg. Volume2,574,156

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsPersistently very high gross margins indicate attractive unit economics for the company’s products. Structurally, high gross profit per unit provides room to absorb fixed R&D and SG&A as revenue scales, enabling operating leverage and a clearer path to durable profitability if top-line growth sustains.

Sharp Revenue Rebound (2025)A large revenue rebound demonstrates the company can restore or expand commercial traction after setbacks. Over a multi-month horizon this improves the potential to spread fixed costs, validate product-market fit, and convert high gross margins into improved operating margins if the growth is maintained or repeated.

Conservative Balance Sheet (no Debt)No reported debt reduces near-term solvency risk and interest burden, preserving financial flexibility. Structurally this gives management optionality to raise equity or enter partnerships without immediate leverage constraints, which matters while the company works to stabilize cash flow and reach positive operating results.

Bears Say

Deep And Worsening Net LossesExtremely large and deteriorating net losses show expenses far outstrip revenues and are eroding capital. Over the medium term this threatens continuity of operations absent durable revenue growth or cost cuts, increases financing needs, and signals structural profitability issues rather than a short-term margin blip.

Consistent Negative Operating & Free Cash FlowPersistent negative OCF and FCF mean the business cannot self-fund operations or investments. This structural cash burn forces reliance on external financing, heightens dilution and refinancing risk, and constrains strategic options, making long-term execution dependent on sustained capital access or rapid cash-flow improvement.

Negative Returns On EquityProlonged deeply negative ROE indicates the company is destroying shareholder value rather than generating returns on invested capital. Structurally, this undermines investor confidence, raises the probability of equity dilution or restructuring, and signals that business economics need material improvement to justify capital allocation.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥48.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥3.07B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.02 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.02.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 60,271,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥4.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.063%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.